FIG 9.

NeoB had a multigenotypic anti-HCV effect and exhibited a synergistic anti-HCV activity when combined with known anti-HCV agents. (A) An HCV replicon assay was performed using replicons of genotypes 1b (NN) and 2a (JFH-1). (B to E) Cotreatment of NeoB with IFN-α, telaprevir (an HCV protease inhibitor), sofosbuvir (a polymerase inhibitor), or daclatasvir (an NS5A inhibitor). HCV-infected Huh7.5.1 cells were treated with the indicated concentrations and combinations of compounds for 72 h. HCV infectivity in the culture supernatant and cell viability were determined as described in the legend of Fig. 1E. The results were analyzed for a synergy plot as described in Materials and Methods. The three-dimensional plots show the difference between theoretical additive effects and the actual experimental effects provided by combination treatments. The zero plane across the z axis indicates the theoretical additive effects. Positive and negative values in the z axis indicate synergy and antagonism, respectively. *, P < 0.05; **, P < 0.01.